[go: up one dir, main page]

WO2002072016A3 - Procede de prevention d'adherences par ifn-¿y? - Google Patents

Procede de prevention d'adherences par ifn-¿y? Download PDF

Info

Publication number
WO2002072016A3
WO2002072016A3 PCT/US2002/007290 US0207290W WO02072016A3 WO 2002072016 A3 WO2002072016 A3 WO 2002072016A3 US 0207290 W US0207290 W US 0207290W WO 02072016 A3 WO02072016 A3 WO 02072016A3
Authority
WO
WIPO (PCT)
Prior art keywords
ifn
enhancers
preventing adhesions
adhesion formation
event
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/007290
Other languages
English (en)
Other versions
WO2002072016A2 (fr
Inventor
Michael P Diamond
Ghassan M Saed
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wayne State University
Original Assignee
Wayne State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wayne State University filed Critical Wayne State University
Priority to AU2002257027A priority Critical patent/AU2002257027A1/en
Publication of WO2002072016A2 publication Critical patent/WO2002072016A2/fr
Publication of WO2002072016A3 publication Critical patent/WO2002072016A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des procédés de prévention de la formation et du développement d'adhérences consistant à administrer des préparations thérapeutiques à un patient. Ces préparations contiennent pour ingrédients actifs des activateurs IFN-y ou IFN-y. Ces activateurs IFN-y ou IFN-y sont administrés de préférence à des tissus fibrosés chez un sujet avant un événement causant la formation d'adhérences, tel qu'un événement chirurgical.
PCT/US2002/007290 2001-03-13 2002-03-11 Procede de prevention d'adherences par ifn-¿y? Ceased WO2002072016A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002257027A AU2002257027A1 (en) 2001-03-13 2002-03-11 Method of preventing adhesions with ifn-y

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27538101P 2001-03-13 2001-03-13
US60/275,381 2001-03-13

Publications (2)

Publication Number Publication Date
WO2002072016A2 WO2002072016A2 (fr) 2002-09-19
WO2002072016A3 true WO2002072016A3 (fr) 2003-02-13

Family

ID=23052048

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/007290 Ceased WO2002072016A2 (fr) 2001-03-13 2002-03-11 Procede de prevention d'adherences par ifn-¿y?

Country Status (2)

Country Link
AU (1) AU2002257027A1 (fr)
WO (1) WO2002072016A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4877619A (en) * 1986-08-25 1989-10-31 Vestar, Inc. Liposomal vesicles for intraperitoneal administration of therapeutic agents
US5885829A (en) * 1996-05-28 1999-03-23 The Regents Of The University Of Michigan Engineering oral tissues

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4877619A (en) * 1986-08-25 1989-10-31 Vestar, Inc. Liposomal vesicles for intraperitoneal administration of therapeutic agents
US5885829A (en) * 1996-05-28 1999-03-23 The Regents Of The University Of Michigan Engineering oral tissues

Also Published As

Publication number Publication date
WO2002072016A2 (fr) 2002-09-19
AU2002257027A1 (en) 2002-09-24

Similar Documents

Publication Publication Date Title
WO2004071529A3 (fr) Utilisations d'anticorps contre le recepteur de facteur de croissance insulinoide i
WO2002100390A3 (fr) Methode amelioree de traitement du syndrome des facteurs de risque de coronaropathie chez l'etre humain
WO2003000343A3 (fr) Administration d'inhibiteurs de phosphodiesterase destinee au traitement de l'ejaculation precoce
WO2003080021A3 (fr) Preparation
CA2446435A1 (fr) Derives 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine
WO2006008639A8 (fr) Traitement combine pour malignites non hematologiques par anticorps anti -ogf-1r
WO2004112711A3 (fr) Composition orale a liberation prolongee
WO2006082588A3 (fr) Procede et dispositif d'administration ophtalmique d'ingredients pharmaceutiquement actifs
WO2001095899A8 (fr) Compositions pharmaceutiques renfermant des derives de cannabidiol
WO2002019969A3 (fr) Acide (5-(2-hydroxy-4-chlorobenzoyl) aminovalerique et ses sels, compositions contenant l'acide et ses sels pour acheminer des agents actifs
WO2001090091A8 (fr) Inhibiteurs de 11-beta-hydroxy-steroide-deshydrogenase de type 1
WO2001078698A3 (fr) Utilisation des antagonistes du ngf dans la prevention et le traitement de la douleur viscerale chronique
WO2002089778A3 (fr) Systeme therapeutique transdermique destine au traitement de la maladie de parkinson induisant des niveaux de plasma eleves de rotigotine
WO2005065319A3 (fr) Forme galenique de fentanyl generalement lineaire effervescente et orale et ses procedes d'administration
CA2294921A1 (fr) Levobupivacine et son utilisation
WO2002088100A3 (fr) 3-piperidinopropiophenones dopees et produits pharmaceutiques contenant ces composes
WO2000078294A3 (fr) Forme galenique orale servant a administrer une combinaison fixe de tramadol et de diclofenac
WO2005044187A3 (fr) Preparations pharmaceutiques inhalables employant de l'anhydrate de lactose, et methodes d'administration desdites preparations
MXPA05013270A (es) Forma de administracion transmucosal con irritacion mucosal reducida. reducida.
WO2001045715A3 (fr) Formulations d'agonistes d'adenosine a1
EP1262197A3 (fr) Combinaison thérapeutique pour traiter les troubles du sommeil, y compris l'apnée du sommeil
CA2385755A1 (fr) Prevention du cancer colorectal
AU2003269792A1 (en) Pharmaceutical formulation of olanzapine
WO2003018535A3 (fr) Nouvelles aminobenzophenones
WO2003007876A3 (fr) Conjugues acide amine-acide gras normal et utilisations therapeutiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10471892

Country of ref document: US

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP